Literature DB >> 463869

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.

L B Schonberger, D J Bregman, J Z Sullivan-Bolyai, R A Keenlyside, D W Ziegler, H F Retailliau, D L Eddins, J A Bryan.   

Abstract

Because of an increase in the number of reports of Guillian-Barre syndrome (GBS) following A/New Jersey influenza vaccination, the National Influenza Immunization Program was suspended December 16, 1976 and nationwide surveillance for GBS was begun. This surveillance uncovered a total of 1098 patients with onset of GBS from October 1, 1976, to January 31, 1977, from all 50 states, District of Columbia, and Puerto Rico. A total of 532 patients had recently received an A/New Jersey influenza vaccination prior to their onset of GBS (vaccinated cases), and 15 patients received a vaccination after their onset of GBS. Five hundred forty-three patients had not been recently vaccinated with A/New Jersey influenza vaccine and the vaccination status for 8 was unknown. Epidemiologic evidence indicated that many cases of GBS were related to vaccination. When compared to the unvaccinated population, the vaccinated population had a significantly elevated attack rate in every adult age group. The estimated attributable risk of vaccine-related GBS in the adult population was just under one case per 100,000 vaccinations. The period of increased risk was concentrated primarily within the 5-week period after vaccination, although it lasted for approximately 9 or 10 weeks.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 463869     DOI: 10.1093/oxfordjournals.aje.a112795

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  166 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 2.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 3.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Influenza and cardiovascular disease: is there a causal relationship?

Authors:  Mohammad Madjid; Ibrahim Aboshady; Imran Awan; Silvio Litovsky; S Ward Casscells
Journal:  Tex Heart Inst J       Date:  2004

Review 5.  The 2009 influenza A (H1N1) pandemic: what have we learned in the past 6 months.

Authors:  Carlos del Rio; Jeannette Guarner
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

Review 6.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

Review 7.  Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination.

Authors:  Eitan Israeli; Nancy Agmon-Levin; Miri Blank; Joab Chapman; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

8.  Characterization of immunological cross-reactivity between enterotoxigenic Escherichia coli heat-stable toxin and human guanylin and uroguanylin.

Authors:  Arne M Taxt; Yuleima Diaz; Amélie Bacle; Cédric Grauffel; Nathalie Reuter; Rein Aasland; Halvor Sommerfelt; Pål Puntervoll
Journal:  Infect Immun       Date:  2014-04-28       Impact factor: 3.441

Review 9.  2009 H1N1 influenza.

Authors:  Seth J Sullivan; Robert M Jacobson; Walter R Dowdle; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2009-12-10       Impact factor: 7.616

Review 10.  Guillain-Barré syndrome. Clinical manifestations and directions for treatment.

Authors:  J Rees
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.